{"url_path":"/sec/anip/8-k/2026-03-03/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-03-03","source_url":"https://www.sec.gov/Archives/edgar/data/1023024/0001023024-26-000017-index.html","accession_number":"0001023024-26-000017","cik":"0001023024","ticker":"ANIP","issuer_name":"ANI PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1023024/0001023024-26-000017-index.html","primary_entity_key":"0001023024","primary_entity_name":"ANI PHARMACEUTICALS INC"},"word_count":89,"has_tables":true,"body_markdown":"Item 7.01Regulation FD Disclosure\n\nOn March 3, 2026, Nikhil Lalwani, President & CEO of ANI Pharmaceuticals, Inc. (the “Company”) along with members of the Company’s executive leadership team, will present at the Raymond James & Associates’ 47th Annual Institutional Investors Conference in Orlando, Florida, and the Company is providing an updated investor presentation. The Company may use the updated investor presentation in various meetings with investors and analysts from time to time. A copy of the investor presentation is attached as Exhibit 99.1 hereto and incorporated herein by reference.*"}